Page 29 - Read Online

Page 260 Lyulcheva-Bennett et al. J Transl Genet Genom 2023;7:259-73 https://dx.doi.org/10.20517/jtgg.2023.33

initiatives. Collaborative research efforts in the future hold the potential to offer transformative insights and
improved outcomes for affected individuals and their families.

Keywords: Moebius syndrome, Möbius syndrome, facial paralysis, facial palsy, CNVI palsy, CNVII palsy,
neurodevelopment, aetiology, multidisciplinary management

INTRODUCTION
Moebius Syndrome (MBS) serves as a paradigmatic example in the field of neurodevelopmental disorders,
highlighting the intricate and often elusive interplay between developmental biology, genetic
predispositions, and environmental determinants in disease aetiology. The syndrome’s initial clinical
[1]
delineation can be traced back to the observations of German ophthalmologist Alfred Von Gräfe in 1880 .
However, it was subsequently named after Paul Möbius, a German neurologist who, in 1888 , published a
[2]
more comprehensive clinical characterisation of the disorder.
MBS is a rare congenital disorder characterised by facial paralysis and ocular abduction defects in the
presence of full vertical gaze . Neonates with MBS often present with distinctive clinical markers, such as
[3]
asymmetrical or “expressionless” facies, feeding difficulties, and an inability to achieve complete eyelid
closure. Cases with unilateral manifestations, which are occasionally attributed to perinatal trauma , can
[4]
present diagnostic ambiguities, necessitating a more nuanced clinical evaluation. Beyond these primary
manifestations, MBS exhibits a much broader clinical spectrum, encompassing a range of associated
congenital anomalies. These can range from limb and cardiac abnormalities to craniofacial dysmorphisms,
adding layers of complexity to its clinical and diagnostic profile .
[5]

Current epidemiological data on MBS prevalence remain somewhat nebulous, with estimates suggesting a
range from 1 in 50,000 to 1 in 500,000 individuals . It is noteworthy that this non-progressive syndrome
[6]
exhibits a pan-ethnic and pan-gender distribution, emphasising its universal clinical relevance .
[3]
The pathogenesis and underlying molecular mechanisms of MBS remain poorly understood . While a
[7]
handful of familial cases provide tantalising hints towards potential genetic underpinnings , the broader
[8]
landscape of genetic and environmental interactions, especially in the context of the cranial nerve
developmental anomalies characteristic of MBS, remains to be fully delineated .
[9]
Historically, the relative rarity and inherent diagnostic complexities associated with MBS have led to it being
somewhat marginalised in the broader context of neurodevelopmental research. This historical oversight
underscores the pressing need for more rigorous, multidisciplinary research endeavours. As the scientific
and medical communities deepen their exploration into the intricacies of Moebius Syndrome, it becomes
increasingly evident that a holistic, integrative approach is essential. Delving into the genetic basis of MBS
not only offers insights into its pathogenesis but also holds the potential to revolutionise therapeutic
interventions . This paves the way for precision medicine tailored to the individual’s genetic makeup .
[10]
[4]
Such an approach should not only aim to unravel the molecular, genetic, and clinical characteristics of the
syndrome but also to develop and refine management strategies and support frameworks for affected
[11]
individuals and their families. By doing so, we can significantly enhance patient outcomes , improve
quality of life, and broaden our understanding of this enigmatic neurodevelopmental condition.